The U.S. Food and Drug Administration has approved Cymbalta for chronic back pain and osteoarthritis pain, according to a FDA news release.
Cymbalta, which was first used to treat major depressive disorder in 2004, is also approved for the treatment of diabetic peripheral neuropathy, generalized anxiety disorder and maintenance treatment of major depression and fibromyalgia.
More than 29,000 patients have used Cymbalta in clinical trials, and more than 600 patients were studied in the clinical trials involving osteoarthritis and chronic low back pain. The safety evaluation for Cymbalta included review of data from the clinical trials as well as post-marketing data from the previously approved patient populations.
The FDA assessed the efficacy of Cymbalta in chronic low back pain and osteoarthritis in four double-blind, placebo-controlled, randomized clinical trials. At the end of the study period, patients taking Cymbalta had a significantly greater pain reduction compared with placebo.
Read the FDA news release about FDA-approved Cymbalta.
Read other coverage about pain management:
- Community Health Center Grant to Support Pain Management Study
- Transdermal Prescription Pain Products to Reach $9.2B by 2015
Cymbalta, which was first used to treat major depressive disorder in 2004, is also approved for the treatment of diabetic peripheral neuropathy, generalized anxiety disorder and maintenance treatment of major depression and fibromyalgia.
More than 29,000 patients have used Cymbalta in clinical trials, and more than 600 patients were studied in the clinical trials involving osteoarthritis and chronic low back pain. The safety evaluation for Cymbalta included review of data from the clinical trials as well as post-marketing data from the previously approved patient populations.
The FDA assessed the efficacy of Cymbalta in chronic low back pain and osteoarthritis in four double-blind, placebo-controlled, randomized clinical trials. At the end of the study period, patients taking Cymbalta had a significantly greater pain reduction compared with placebo.
Read the FDA news release about FDA-approved Cymbalta.
Read other coverage about pain management:
- Community Health Center Grant to Support Pain Management Study
- Transdermal Prescription Pain Products to Reach $9.2B by 2015